“…According to the draft landscape of COVID-19 candidate vaccines by the World Health Organizations (WHO), there were over 185 candidate vaccines in preclinical evaluations and 102 undergoing clinical evaluations in different phases till June 8 [2] . Among them, the results of phase 1/2 trials of 24 candidate vaccines have been published or made available on preprint servers, including seven protein subunit [3] , [4] , [5] , [6] , [7] , [8] , [9] , six inactivated [10] , [11] , [12] , [13] , [14] , [15] , six recombinant, [16] , [17] , [18] , [19] , [20] , [21] three mRNA, [22] , [23] , [24] one DNA vaccine, [25] and one virus-like particle vaccine [26] . All 24 vaccines demonstrated acceptable safety profiles and immunogenicity.…”